Savara’s (SVRA) Market Outperform Rating Reiterated at JMP Securities

JMP Securities reaffirmed their market outperform rating on shares of Savara (NASDAQ:SVRA) in a research report released on Monday, Benzinga reports. They currently have a $8.00 price target on the stock.

Separately, Piper Sandler lifted their price objective on shares of Savara from $7.00 to $16.00 and gave the company an overweight rating in a report on Monday, March 4th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Savara presently has an average rating of Buy and a consensus price target of $8.20.

Savara Price Performance

Savara stock opened at $4.99 on Monday. Savara has a 12-month low of $1.83 and a 12-month high of $5.70. The company has a current ratio of 15.66, a quick ratio of 15.66 and a debt-to-equity ratio of 0.19. The firm has a 50-day moving average price of $4.89 and a 200-day moving average price of $4.51. The firm has a market capitalization of $689.52 million, a PE ratio of -15.12 and a beta of 0.73.

Savara (NASDAQ:SVRA) last announced its quarterly earnings data on Thursday, March 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.02. As a group, equities research analysts forecast that Savara will post -0.38 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC bought a new position in shares of Savara during the third quarter valued at approximately $140,000. Bank of New York Mellon Corp increased its holdings in shares of Savara by 20.6% in the 3rd quarter. Bank of New York Mellon Corp now owns 261,435 shares of the company’s stock valued at $988,000 after acquiring an additional 44,641 shares during the period. Jennison Associates LLC raised its position in shares of Savara by 44.6% in the 3rd quarter. Jennison Associates LLC now owns 3,866,762 shares of the company’s stock worth $14,616,000 after acquiring an additional 1,192,730 shares in the last quarter. Principal Financial Group Inc. purchased a new stake in shares of Savara during the 3rd quarter worth $48,000. Finally, Jump Financial LLC bought a new stake in Savara during the third quarter valued at about $123,000. 87.93% of the stock is currently owned by institutional investors.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.